Initial clinical applications of TSPO PET in gliomas are interesting, particularly concerning the potential for its following applications: (1) in vivo assessment of glioma biological aggressiveness; (2) evaluation of glioma-associated TME, potentially amenable to molecularly targeted therapies; (3) prediction of survival after recurrence. The gene discussed is TSPO; the disease is central nervous system cancer.